AUTHORS
Hadrian Mendoza, MD, Yevgeniya Foster, MD2, Iris Isufi, MD3, Scott F. Huntington, MD, MPH4, Natalia Neparidze, MD5, Cristian Camilo Taborda, MD6, Jessica Maria Stempel, MD, MHS7, Lourdes Mendez, MD, Ph D8, Maximilian Stahl, MD9, Jan Philipp Bewersdorf, MD10, Luis E. Aguirre, MD, MPH11, Amer M. Zeidan, MD12, Nikolai Podoltsev, MD, PhD13
AFFILIATIONS
1 Yale School of Medicine, New Haven, Connecticut, United States
2 Yale School of Medicine, New Haven, Connecticut, United States
3 Yale School of Medicine, New Haven, Connecticut, United States
4 Yale School of Medicine, New Haven, Connecticut, United States
5 Yale School of Medicine, New Haven, Connecticut, United States
6 Yale School of Medicine, New Haven, Connecticut, United States
7 Oregon Health Sciences University, Portland, Oregon, United States
8 Yale School of Medicine, New Haven, Connecticut, United States
9 Yale School of Medicine, New Haven, Connecticut, United States
10 Yale School of Medicine, New Haven, Connecticut, United States
11 Yale School of Medicine, New Haven, Connecticut, United States
12 Yale School of Medicine, New Haven, Connecticut, United States
13 Yale School of Medicine, New Haven, Connecticut, United States
ABSTRACT
Background: Acquired aplastic anemia (AA) is an uncommon cause of bone marrow failure that rarely occurs with lymphoid malignancies. The pathogenesis of AA in patients (pts) with lymphoid malignancy is poorly understood, and guidelines do not address the treatment approach in this scenario. For pts with severe (SAA) or very severe AA (VSAA) who are not candidates for allogeneic hematopoietic stem cell transplantation (HCT), standard first-line management consists of immunosuppressive therapy (IST) including horse antithymocyte globulin (hATG) and cyclosporine (CsA), plus the thrombopoietin receptor agonist eltrombopag (EPAG). Advanced age, frailty, and comorbidities may limit the use of hATG. Clinicians may defer IST while treating the lymphoid malignancy, although whether malignancy-directed therapy improves marrow failure is unknown.
Methods: We performed a retrospective single-center study of pts with concurrent AA and lymphoid malignancy diagnosed and managed between 2016 and 2025. AA severity was classified according to modified Camitta criteria, and AA-directed treatment responses were assessed at 6 months for surviving pts using established criteria (Townsley, et al. NEJM 2017). We characterized the temporal relationship, treatment sequencing, hematologic responses, and outcomes of adults with AA and lymphoid malignancy.
Results: Fourteen pts were identified. Median age at AA diagnosis was 69 years (range, 61–78), and 8 (57%) were male. Five (36%) had SAA, 5 (36%) had VSAA, and 4 (28%) had non-severe AA (NSAA). Lymphoid malignancies included multiple myeloma (MM, n=5), lymphoplasmacytic lymphoma (LPL, n=3), chronic lymphocytic leukemia (n=3), angioimmunoblastic T-cell lymphoma (AITL, n=1), marginal zone lymphoma (n=1), and follicular lymphoma (FL, n=1). Five pts presented with AA concurrently, 1 before, and 8 after a diagnosis of lymphoid malignancy. Three of the latter may initially have had unrecognized AA (diagnosed with immune thrombocytopenia [ITP] refractory to ITP therapy).
No patient had evidence of a myeloid neoplasm on diagnostic bone marrow examination. In follow-up, 1 patient with MM and 1 with FL developed monosomy 7-associated myelodysplastic syndrome at 6 months; both subsequently underwent HCT and achieved complete remission (CR). No additional pts underwent HCT during the observation period. Small paroxysmal nocturnal hemoglobinuria (PNH) clones were detected at diagnosis in 7 of 12 tested pts, supporting an autoimmune, T-cell-mediated mechanism of marrow failure analogous to idiopathic AA. Two pts had testing for large granular lymphocyte expansions by flow cytometry, both of which were positive, though T-cell clonality testing was negative. One had a concurrent PNH clone.
Among 10 pts with SAA/VSAA, 8 received IST with overall response rate of 37.5% (all with partial response [PR]). Only 3 pts received standard hATG/CsA/EPAG; all 3 achieved PR at 6 months. The remaining 5 pts, who were considered unsuitable for hATG due to poor performance status, received CsA+EPAG, did not respond, and died from AA-related complications. Of the 2 remaining pts with SAA/VSAA who received no AA-directed therapy, 1 achieved CR following MM-directed therapy, and the other died after non-response to LPL therapy. All pts receiving IST were initially treated for their lymphoid malignancy based on the rationale that AA may represent a paraneoplastic manifestation of the underlying malignancy. However, only 1 of 10 pts treated for lymphoid malignancy (MM) experienced CR of AA, while no other patient demonstrated meaningful improvement in AA following lymphoma- or MM-directed therapy. Among 4 pts with NSAA, 2 were managed with observation, 1 received CsA, and 1 received CsA+EPAG; the latter 2 achieved PR.
After a median follow-up of 15.5 months, 7 of 14 pts had died, predominantly from AA-related complications rather than progression of lymphoid malignancy.
Conclusions: AA diagnosed concurrently with lymphoid malignancy appears to represent an immune-mediated bone marrow failure syndrome rather than treatment-related toxicity. Treatment of the underlying lymphoid malignancy rarely improved AA, whereas delaying AA-directed therapy was associated with clinical deterioration that precluded hATG-based IST. These findings support early evaluation for standard hATG-based IST in eligible pts with SAA/VSAA and concurrent lymphoid malignancy, rather than deferring AA-directed therapy until after lymphoma- or MM-directed treatment.
DISCLOSURES
Hadrian Mendoza, MD: No relevant conflicts of interest to declare.